Literature DB >> 25740782

DNA sequencing for confirmation of rifampin resistance detected by Cepheid Xpert MTB/RIF assay.

Allison J McAlister1, Jeffrey Driscoll2, Beverly Metchock2.   

Abstract

DNA sequencing of rpoB and culture-based drug susceptibility results were evaluated for samples referred for confirmation of rifampin resistance detected by the Cepheid Xpert MTB/RIF assay. Silent mutations and mutations associated with low-level resistance were found in the study population. These data support CDC recommendations to confirm Xpert rifampin resistance results.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25740782      PMCID： PMC4400788          DOI： 10.1128/JCM.03433-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient?

Authors:  M Yagui; M T Perales; L Asencios; L Vergara; C Suarez; G Yale; C Salazar; M Saavedra; S Shin; O Ferrousier; P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2006-08       Impact factor: 2.373

2.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

3.  Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category.

Authors:  María Alonso; Juan José Palacios; Marta Herranz; Ana Penedo; Angela Menéndez; Emilio Bouza; Darío García de Viedma
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

4.  Diagnosis of tuberculosis and drug resistance: what can new tools bring us?

Authors:  F Drobniewski; V Nikolayevskyy; Y Balabanova; D Bang; D Papaventsis
Journal:  Int J Tuberc Lung Dis       Date:  2012-07       Impact factor: 2.373

5.  Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  Patricia J Campbell; Glenn P Morlock; R David Sikes; Tracy L Dalton; Beverly Metchock; Angela M Starks; Delaina P Hooks; Lauren S Cowan; Bonnie B Plikaytis; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

6.  False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.

Authors:  V Mathys; M van de Vyvere; E de Droogh; K Soetaert; G Groenen
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

7.  Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations.

Authors:  Leen Rigouts; Mourad Gumusboga; Willem Bram de Rijk; Elie Nduwamahoro; Cécile Uwizeye; Bouke de Jong; Armand Van Deun
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

8.  Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-10-18       Impact factor: 17.586

9.  Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results.

Authors:  Oksana Ocheretina; Vincent E Escuyer; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Sean Collins; Stalz C Vilbrun; Jean W Pape; Daniel W Fitzgerald
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240
  9 in total
  8 in total

1.  Direct Detection of Rifampin and Isoniazid Resistance in Sputum Samples from Tuberculosis Patients by High-Resolution Melt Curve Analysis.

Authors:  Divya Anthwal; Rakesh Kumar Gupta; Manpreet Bhalla; Shinjini Bhatnagar; Jaya Sivaswami Tyagi; Sagarika Haldar
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

Review 2.  Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.

Authors:  Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

3.  Performance of TaqMan array card to detect TB drug resistance on direct specimens.

Authors:  Sayera Banu; Suporn Pholwat; Suporn Foongladda; Rattapha Chinli; Duangjai Boonlert; Sara Sabrina Ferdous; S M Mazidur Rahman; Arfatur Rahman; Shahriar Ahmed; Eric R Houpt
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

4.  What tuberculosis can teach us about combating multidrug-resistant Gram negative bacilli.

Authors:  Ritu Banerjee; Jeffrey R Starke
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-04-01

5.  Evaluation of whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant Mycobacterium tuberculosis isolates from Ningbo, China.

Authors:  Yang Che; Yi Lin; Tianchi Yang; Tong Chen; Guoxin Sang; Qin Chen; Tianfeng He
Journal:  Front Public Health       Date:  2022-08-18

6.  Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012.

Authors:  Joanna Spinato; Élyse Boivin; Émilie Bélanger-Trudelle; Huguette Fauchon; Cécile Tremblay; Hafid Soualhine
Journal:  BMC Microbiol       Date:  2016-07-26       Impact factor: 3.605

Review 7.  Molecular Diagnosis of Tuberculosis.

Authors:  Fariz Nurwidya; Diah Handayani; Erlina Burhan; Faisal Yunus
Journal:  Chonnam Med J       Date:  2018-01-25

8.  Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.

Authors:  Jason P Rice; Marva Seifert; Kathleen S Moser; Timothy C Rodwell
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.